Afrezza is a rapid-acting inhaled human insulin indicated to improve glycemic control in adults with diabetes mellitus.
BioArctic AB's (publ) (STO: BIOA B) partner Eisai announced today that the supplemental Biologics License Application (sBLA) for Leqembi Iqlik subcutaneous autoinjector (SC-AI) as a weekly starting ...
BioDlink, a leading global contract development and manufacturing organization (CDMO), has released a white paper titled ...
New FDA-cleared version with tool detection and CE-marked version with additional quality (CAQ) features further strengthen MAGENTIQ-COLO's AI platform HAIFA, IL / ACCESS Newswire / January 26, 2026 / ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results